PRODUCT SRARCH
Welcome to use the web search system, you can enter the product name or product CAS number to search product . If you have any questions or sugesstions, please contact us.
|
| Cas No. |
Product name |
| 257933-82-7 |
Pelitinib (EKB-569) |
more... |
| Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Phase2 |
| 698387-09-6 |
Neratinib (HKI-272) |
more... |
| Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2... |
| 1032900-25-6 |
LDK378 |
more... |
| LDK378 is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3. |
| 877399-52-5 |
Crizotinib (PF2341066) |
more... |
| PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley |
| 956905-27-4 |
PF04217903 |
more... |
| PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1. |
| 928037-13-2 |
Golvatinib（E7050) |
more... |
| Golvatinib(E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyr... |
| 1025720-94-8 |
BMS777607 |
more... |
| BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, 40-fold more selective for Met-related targets versus Lck,... |
| 1029712-80-8 |
INCB28060 |
more... |
| INCB28060 is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM, inactive against RONβ, as well as EGFR and HER-3. Phase 1. |
| 849217-64-7 |
Foretinib (GSK1363089) |
more... |
| Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGF... |
| 1022150-57-7 |
SGX-523 |
more... |
| SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1. |
|
